Mirum Pharmaceuticals, Inc.
VANTAGE
Fragile X syndrome
Countdown
177days
Phase 2 readout · ~ Dec 31, 2026 estimated
What's at stake
Phase 2 trial results for VANTAGE in Fragile X syndrome are due ~ Dec 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“VANTAGE Phase 2b positive interim analysis, expect enrollment completion H2 2026”